Arkema Grants an Exclusive Technology License to SEQENS to manufacture PEKK for sale in Long Term Medical Implantable Applications
SEQENS, an integrated global player in solutions and ingredients for the pharmaceutical and specialty market, is excited to announce a new step in its collaboration with Arkema, a world leader in specialty materials, with the signature of an exclusive technology license for the manufacturing of PEKK for sale in long term implantable applications.
The two companies have partnered for 15 years, combining Arkema’s expertise and intellectual property in PEKK technology together with SEQENS’ recognized know-how in the production of polymers for the pharmaceutical and life sciences markets.
PEKK is a high-performance polymer family used in aerospace and other demanding markets, commercialized by Arkema under the Kepstan® trademark. SEQENS’ IMPEKK materials have been specifically developed for long term medical implantable applications. IMPEKK materials will be provided to the market by SEQENS through a global network of partners, including well-known manufacturers, 3D printing machine companies, and distributors.
source:SEQENS
Comments
Post a Comment